The Food and Drug Administration (FDA) conducted an inspection of Plasma, Inc., BPC in Jacksonville on March 25, reviewing the facility for blood and blood products compliance, according to data posted on the FDA’s website.
The inspection’s final report stated no corrective actions were required for Plasma, Inc., BPC in its organizational operations.
The FDA regularly conducts inspections nationwide to assess whether workplaces and products meet agency regulations aimed at safeguarding public health. Inspection outcomes are made available to the public.
According to its website, the FDA serves as a government agency overseeing the safety and quality of human and animal drugs, biological products, medical devices, and tobacco products.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
